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Helicobacter pylori (H. pylori) is a gram-negative 
bacterium found on the luminal surface of the gastric 
epithelium. The bacterium induces chronic inflammation 
of the underlying mucosa and typically infects the 
stomach in the first few years of life. It was isolated for 
the first time by Marshall and Warren.1-3 It survives in the 
acidic environment of the gastric mucosa and causes 
gastritis, peptic ulcers, mucosa-associated lymphoid 
tissue lymphoma, and gastric cancer. Therefore, the erad-
ication of H. pylori can markedly lower gastric and 
duodenal ulcer recurrence and allowing the treatment of 
mucosa-associated lymphoid tissue lymphoma.2-5  
H. pylori treatment continues to be a challenge for 
physicians as antimicrobial resistance has continued to 
increase worldwide in part due to overuse of antibiotics 
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ABSTRACT 
Background: High prevalence of Helicobacter pylori infection and induction of resistance as a result of consumption 
of antibiotics necessitates an ongoing effort for evaluation of new regimen to overcome this phenomenon.  Intensive 
efforts are being made to identify such an optimal regimen, but there are many obstacles hindering the achievement of 
this goal. This study aimed to investigate the impact of adding bismuth to rabeprazole, amoxicillin and clarithromycin 
on rate of H. pylori eradication. 
Methods: In this randomized clinical trial, 60 patients with dyspepsia and positive gastric biopsy for H. pylori in 
endoscopy were recruited. The first group (A) received rabiprazole for 6 weeks, amoxicillin and clarithromycin for 2 
weeks either with bismuth for 2 weeks and the second group (B) received rabiprazole for 6 weeks, amoxicillin and 
clarithromycin for 2 weeks either without bismuth. Four weeks after the treatment, the compliance and eradication 
were evaluated using stool antigen of helicobacter. The patients who could complete the therapeutic regimen were 
assigned for analysis. 
Results: H. pylori eradication rates were 70% and 56.6% in two groups A and B (with and without Bismuth), 
respectively and the difference was significant. There is a significant relationship between the studied groups and the 
results of fecal antigen of H. pylori. 
Conclusions: The bismuth had a significant effect on the success of eradication rate of H. pylori and its impact 
adding to the treatment regimen containing clarithromycin was effective on eradication success rate. 
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in medicine and agriculture.6 While many international 
guidelines still recommend standard triple therapy as a 
first line therapy, they often include a caveat about the 
problem of increasing clarithromycin resistance. Several 
recent large clinical trials and meta-analyses have shown 
that the eradication rate of standard triple therapy has 
generally declined to unacceptable levels (i.e., 80% or 
less) with some European studies reporting failure rates 
of 25-60%.5-7 Several strategies including bismuth-
containing and non-bismuth-containing quadruple 
therapies (including sequential, concomitant and hybrid 
therapies) have been shown to produce acceptable cure 
rates in the presence of clarithromycin resistance.8-10  
The first-line choice of treatment for H. pylori infection 
in the United States and Europe consists of a 
conventional triple therapy, in which a proton pump 
inhibitor (PPI), clarithromycin, and amoxicillin are 
administered for 7-14 days.4-6 Conventional triple therapy 
is also recommended as a first-line therapy by Asian-
Pacific and Brazilian consensus groups.7,8 However, over 
the past few years, the efficacy of conventional triple 
therapy has decreased, with eradication rates of <80%, 
especially in the region with high clarithromycin 
resistance, including Turkey. Decreased eradication rates 
are due primarily to increased bacterial resistance to 
clarithromycin, indicating the need for new first-line 
treatments.11-14 
Bismuth is cytoprotective and antibacterial agent which 
has been safely used for three centuries. The addition of 
bismuth compounds to different antibiotic combinations 
have been reported to provide a favorable effect on 
eradication rates.15-19 
This study aimed to investigate the impact of adding 
bismuth to rabeprazole, amoxicillin and clarithromycin 
on rate of helicobacter pylori eradication. 
METHODS 
Study design and patients 
From October 2016 to 2017, this study was undertaken at 
Imam Khomeini Hospital of Ardabil city. The study 
subjects were patients with gastric symptoms (dyspepsia) 
and confirmed gastritis, with gastric and duodenal ulcers 
on esophagogastroduodenoscopy and H. pylori infection 
was diagnosed through histologic examination (Giemsa 
stain) of antral and body biopsy samples diagnosed 
histopathologically documented H. pylori infection. 
Patients were considered infected by H. pylori if resulted 
positive.  
The subjects were randomly divided into two groups 
using a random number. The first group was treated with 
Rabiprazole 20 mg (b.i.d, 30 minutes before meals) for 
six weeks, amoxicillin 1000 mg (b.i.d, an hour after 
meals), bismuth sub-citrate 300 mg (equivalent to Bi2O3 
120 mg; two swallowed tablets, an hour before breakfast 
and dinner) and clarithromycin 500 mg (b.i.d, an hour 
after meals) for two weeks (30 patients). The second 
group was treated with rabiprazole for 6 weeks, 
amoxicillin and clarithromycin for 2 weeks (30 patients). 
Four weeks after the treatment period, we confirmed H. 
pylori eradication using fecal antigen of the H. pylori. 
Data collection  
Data collected by a checklist included demographic 
information, history of smoking, alcohol consumption, 
previous upper gastrointestinal bleeding and endoscopic 
findings including, gastritis, erosions, and the presence or 
absence of bulbar deformity. 
Stool antigen test (SAT) 
The stool samples were tested for the presence of H. 
pylori antigen with ELISA method (DIA.PRO, diagnostic 
Bioprobes, Italy) according to the recommendations of 
the manufacturer. 
Inclusion and exclusion criteria  
Patients with dyspepsia and positive gastric biopsy for 
Helicobacter pylori in endoscopy were recruited in the 
study and patients with previous attempt of H. pylori 
eradication therapy; recent use of antibiotic or bismuth 
salts or proton-pump inhibitors in the last 2 months 
before the study, chronic use of nonsteroidal anti-
inflammatory drugs or corticosteroids, severe comorbid 
diseases, gastric malignancy including adenocarcinoma 
and lymphoma; pregnancy or lactation, diarrhea, prior 
gastric surgery, allergy to any of the drugs in the current 
treatment; age under 18 years, were excluded from the 
study. 
Statistical analysis 
Data analysis was performed using statistical software 
package program (SPSS) version 22.0 (IBM, USA). The 
normality of data was checked by K-S test and results 
showed that the distribution of data was normal and we 
used parametric tests for analysis data. Inter group 
comparisons of categorical variables were done using 
Chi-square test and continuous variables were compared 
using student’s t-test. Categorical variables were 
presented as percentages or counts and continuous 
variables were presented as mean and standard deviation 
in descriptive analysis. Results were evaluated at 95% of 
confidence interval (CI), and significance was evaluated 
for each parameter at p<0.05. 
Ethical approval 
The result of this study was approved by Ardabil 
University ethical committee and registered by code IR-
ARUMS-REC 1396-85. Also, this study registered in 
IRCT with code IRCT2017111827097N2. Informed 
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consent was obtained from each patient before enrolling 
into the study. 
RESULTS 
Patient characteristics 
A total of 60 patients were included. Table 1 shows 
baseline characteristics of two groups. Groups did not 
differ with regard to demographical and clinical 
characteristics. There was no difference (p=0.8) between 
the average ages of the groups, which were 51.24±11.87 
(18-66) and 49.7±13.01 (25-75) years in the A and B 
groups, respectively. The male ratios were 36.66 and 43.3 
(p=0.9), respectively. Two groups were matched 
approximately in term of age, education, job and gender 
and the difference between two groups were not 
significant.  
Treatment success 
In the analysis, the successful eradication rate in the 
patients who experienced successful was 70% in the A 
group (95% CI: 0.57-0.72) and for patients in the B group 
was 56.66% (95% CI: 0.61-0.86). There was significant 
difference in eradication rate among the two groups 
(p=0.005) (Table 2).  
Adverse drug reaction  
Of all patients, 21 (35%) reported minor adverse drug 
reactions. The percentages of patients with adverse 
reactions in the A group with 43.3% (13/30) was 
significantly more than B group with 26.6% (8/30) 
(p=0.03).  
 
Figure 1: The frequency of adverse drug reactions in 
all samples. 
In order of frequency, bitter taste, loose stool, headache, 
dark stool, and abdominal bloating were the most 
common adverse reactions in all study group. Dark stool, 
abdominal bloating, and headache were the most 
common adverse reactions in the A group. Bitter taste, 
headache, and loose stool were the most common events 
in the sequential group and in the B group. However, 
these developments were not statistically significant, and 
there were no major adverse reactions (Figure 1). 
Table 1: Characteristics of patients’ N (%). 
Characteristics Group A Group B P value 
Age (years) 51.24±11.87 49.7±13.01 P=0.8  
Gender  
 
Male 11 (36.6) 13 (43.3) P=0.7  
 Female 19 (63.3) 17 (56.6) 
Education 
Illiterate  6 (20) 10 (33.3) 
0.42 Under graduated  21 (70) 18(60) 
Graduated  3 (10) 2 (6.7) 
Job 
Non-employee  26 (86.7) 24 (80) 
0.36 
Employee  4 (3.3) 6 (20) 
Table 2: Eradication rates of H. pylori in two groups.  
Groups Patients (n)  Eradication rate (%)  P value 
A 21/30 70 
p=0.007 
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DISCUSSION 
The major factor affecting the success rate of H. pylori 
eradication is resistance to antibiotics. Resistance rate for 
clarithromycin has been reported as 8-30% and for 
metronidazole as 15-66% in the world.10 Amoxicillin 
resistance has been reported as under 1%. Since the 
presence of dual resistance theoretically removes both 
clarithromycin and metronidazole leaving only the PPI 
and amoxicillin dual regimen. Fourteen days dual therapy 
with standard dose PPI provides approximately 50% of 
treatment success and approximately one-half that at 7 
days. Therefore, Sequential therapy ST (amoxicillin 1 g 
plus a PPI b.i.d. for 5 days, then clarithromycin 500 mg 
and tinidazole or metronidazole 500 mg b.i.d plus a PPI 
b.i.d for remaining 5 days) is likely to be an unacceptable 
choice in regions where both clarithromycin and 
metronidazole resistance are common. Recently, in our 
region, metronidazole resistance was reported to be more 
than 40% and clarithromycin resistance was reported to 
be more than 30%. So that ST is also not suitable 
treatment protocol for our region. Previous studies from 
our country are in accordance with our results.10,20 
There is growing data about useful effects of bismuth 
compounds in H. pylori eradication treatment. Bismuth 
containing quadruple treatment has been showed to 
provide better eradication rates comparing to standard 
triple treatment, and it has been recommended as a first-
line treatment in regions which have high clarithromycin 
rates.9 
As previously mentioned, the use of standard triple 
therapy is not satisfactory for achieving a low eradication 
rate, although the efficacy of this therapy has been 
improved with the addition of bismuth. Xu et al reported 
that 7 days of standard triple therapy plus bismuth 
increased the eradication rate from 66.67% to 82.09% 
according to ITT analysis.20 When the treatment was 
extended to 14 days, the ITT eradication rate reached 
93.7% compared with 80.0% after 7 days of treatment, 
which suggested that the addition of bismuth can 
overcome H. pylori resistance to clarithromycin.21 
Although, bismuth-containing groups is a highly effective 
regimen that could be recommended as a first-line 
therapy, bismuth is not available in many developed 
countries due to its potential nephrotoxicity.22-24 
However, the results of a meta-analysis that included 35 
randomized controlled trials involving 4763 patients 
detected no statistically significant difference in the total 
number of adverse events after the use of bismuth. 
Bismuth is safe and well-tolerated for the treatment of H. 
pylori. Moreover, with the availability of new single 
(three in one) capsule-containing bismuth substrate, 
metronidazole, and tetracycline, the number of tablets 
needs to be taken in the bismuth quadruple group will be 
substantially decreased and this will also likely increase 
drug compliance.25 The only adverse event that occurred 
with significant frequency was dark stools.26 In this 
study, the most adverse reaction of bismuth-containing 
groups was the dark stool, too. Clinicians should, 
however, avoid the prescription of bismuth as a gastric 
mucosa protectant for long-term use. ST has been 
reported to be more effective than standard triple therapy 
in many Asian countries. There was a difference among 
the eradication rates of ST in several countries, with 95%, 
in Thailand; and 89%, in China.23,24 One of these studies 
from our country which is conducted by Ergul et al have 
reported high eradication rates 90.7% with the addition of 
bismuth to the standard triple regimen. However, they 
had not compared the same regimen without bismuth 
simultaneously.22 
Besides the PPI-based treatments which contain PPI, 
amoxicillin, clarithromycin and bismuth, ranitidine 
bismuth-based treatments which contain ranitidine 
bismuth, amoxicillin, and clarithromycin have been also 
reported not to provide sufficient success.23,24 
Administration time of drugs is a very important factor, 
which influence the effectiveness. Bismuth has been 
reported to facilitate the passage of the antibiotic into the 
microorganism. Coadministration of bismuth compounds 
with antibiotics has been demonstrated to reduce 
antibiotic resistance or increase the eradication rates of 
antibiotic resistant strains.27 In an in vitro study, bismuth 
has been found to act as synergistic effect with 
metronidazole and clarithromycin against antibiotic 
resistant H. pylori strains in agar dilution or E-test 
methodology using time-kill method.26 A simple addition 
of bismuth compound to an antibiotic has been suggested 
not to overcome the established antibiotic resistance.26-28 
However in the most applications, using of bismuth has 
been recommended before meal because of it acts at low 
pH and using of antibiotics have been recommended after 
meal because of their dyspeptic side effects. We also 
recommended our patients to use bismuth before meal. 
Since coadministration is more effective than simple 
addition, we may fail to demonstrate the real effect of 
bismuth.  
CONCLUSION 
The results of this study showed that the eradication rate 
of H. pylori in group A was significantly more than group 
B. So, we could result that adding bismuth to rabeprazole, 
amoxicillin and clarithromycin could be effective on H. 
pylori eradication rate. So, this therapeutic method could 
be recommended in future. 
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